 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
|
|
|
|
 |
 |
Criteria: , Region: |
Change Criteria |
 |
|
| |
Note: Should you have landed here as a result of a search engine
(or other) link, be advised that these files contain material which is copyrighted
by the American Medical Association (AMA). You are forbidden to download the files
unless you read, agree to and abide by the provisions of the copyright statement.
Read the copyright statement now
(you will be linked back to here).
 |
National Government Services, Inc.
Medicare Monthly Review Part A and B
|
|
A Combined Part A and Part B Newsletter
|
IssueMonthyear |
Medical Policy Update – Part A/B Contractors
Revised Local Coverage Determination (LCD) and Supplemental Instructions Article (SIA)
Erythropoietin Stimulating Agents (ESA) LCD
Effective April 1, 2008
Erythropoietin Stimulating Agents (ESA) LCD (L25211)
Revision #4 (effective 04/01/2008):
ICD-9-CM 238.4, polycythemia vera, 238.71 essential thrombocythemia and 238.72, low grade myelodysplastic syndrome lesions have been removed from the list of diagnosis allowed for EPO for chemotherapy-induced anemia because these diagnoses are not malignancies.
Note: ICD-9-CM 238.72, low grade myelodysplastic syndrome lesions will remain listed as a covered indication.
Language was updated to define nationally noncovered indications of ESA treatment.
No additional comment or notice periods required and none given.
ESA SIA ( A44399 ) Article will be published April 1, 2008:
Reporting of hematocrit or hemoglobin levels on all claims for the administration of erythropoiesis stimulating agents (ESAs), implementation of new modifiers for non-ESRD indications, and reporting of hematocrit/ hemoglobin levels on all non-ESRD, non-ESA claims for requesting payment for anti-anemia drugs.
Language was updated to define claims processing rules for ESAs administered to cancer patients for anti-anemia therapy.
|
|
 |
|
  |
|
|
 |
|
|
| |
|
| |
Untitled Page
|
Untitled Page
|
|
|
|
|
|